Navigation Links
Seambiotic Appoints New CEO
Date:9/14/2009

ASHKELON, Israel, Sept. 14 /PRNewswire/ -- Seambiotic, a global leader in the development and production of marine microalgae for the nutraceuticals and biofuel industries, has announced that Daniel Chinn has been appointed Chief Executive Officer of the company effective immediately. Daniel replaces founder and previous CEO Amnon Bechar who has been appointed to a new role of Chief Operating Officer.

Daniel joins Seambiotic following a career in law and venture capital. Following a law degree at University College, Oxford University, Daniel started his professional career at Herzog, Fox & Neeman where he spent 12 years, ending his time there as an M&A partner in the international department specializing in representation of multinational corporations. In 2000, Daniel joined Israel Seed Partners, an Israeli venture capital fund with close to $300M under management.

"I am very excited about joining Seambiotic at this turning point in its development," said Chinn. "Seambiotic has proven its model for microalgae cultivation and has been inundated with requests for partnerships and joint projects. I hope that I will be able to help Seambiotic move smoothly through the next phases of its growth as it becomes a major player in the industry."

Seambiotic (http://www.seambiotic.com/) was founded in 2003 to grow and process marine microalgae for the nutraceutical and biofuel industries. Seambiotic's research efforts include a pilot study at an Israeli Electric Corporation power station near the city Ashkelon, Israel, where various species of marine microalgae have been successfully cultivated using the power station's CO2 emissions released directly from their smokestacks; the microalgae are in turn sold into the nutraceutical market or used as feedstock for animal or fish and biofuel. Seambiotic's technology reduces the cost of microalgae production significantly while lowering global warming by reducing industrial CO2 emissions. The company is currently in transition from the pilot plant stage to commercial scale algae cultivation and production.

    Contact:
    Osnat Dobzinski
    Seambiotic Ltd.
    Tel:  +972 3 6911 688
    Email: osnat@seambiotic.com


'/>"/>
SOURCE Seambiotic Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seambiotic USA and NASA Glenn Research Center Signed Agreement for Large Scale Microalgae Process Optimization
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017  Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
(Date:2/23/2017)... INDIANAPOLIS, Ind. (PRWEB) , ... February 23, 2017 ... ... Commercialization Award during the 12th annual Inventors Recognition Reception at Purdue Research ... annually to a faculty member in recognition of outstanding contributions to, and success ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel , a ... Systems, LLC (KRS) clinical development program. KRS is a neurotechnology spin-out from ... and clinical applications. The terms of the transaction were not disclosed. , ...
Breaking Biology Technology:
(Date:1/30/2017)... SAN FRANCISCO , Jan. 30, 2017   ... of the fastest growing genetic information companies, today announced ... 2016 financial results and provide 2017 guidance on Monday, ... a conference call that day at 4:45 p.m. Eastern ... call, Invitae,s management team will briefly review financial results, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 According to ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is ... from 2016 to 2022. In 2015, Asia-Pacific dominated the ... public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):